BOSTON ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for October: Oct. 5-6 JMP Securities Healthcare Focus conference Oct. 7-8 Cowen & Co. 12 th Annual Therapeutics Conference Oct. 8 FDA approval decision date for Spectrum Pharmaceuticals' ( SPPI) colon cancer drug Fusilev. Oct. 13 Presentation at the American Neurological Association meeting of detailed data from the phase III study of Avanir Pharmaceuticals' ( AVNR) Zenvia, an experimental drug for the treatment of uncontrollable laughing and crying episodes -- a condition known medically as pseudobulbar affect. Avanir announced positive top-line results from this study in August. Third-quarter earnings: Johnson & Johnson ( JNJ) (before market open) and Gilead Sciences ( GILD) (after market close.) Oct. 14 The FDA's Peripheral and Central Nervous System Drug Advisory Committee will convene to review Acorda Therapeutics' ( ACOR) fampridine (brand name Amaya). The proposed indication for Amaya is to improve the walking ability of patients with multiple sclerosis. Biogen Idec ( BIIB) is Acorda's marketing partner for Amaya. Take note: The FDA's briefing documents for Amaya should be posted to the agency's web site on Oct. 12 or 13. When available, those documents can be found here. Third-quarter earnings: Abbott Labs ( ABT) (before market open.) Oct. 15 Third-quarter earnings: Cubist Pharmaceuticals ( CBST) (after market closes.) Oct. 16-21 The American College of Rheumatology annual meeting in Philadelphia. Noteworthy clinical data expected for presentation includes Pfizer's ( PFE) CP-690550 in rheumatoid arthritis and Rigel Pharmaceuticals' ( RIGL) R788 in rheumatoid arthritis Oct. 19 FDA approval decision date for Amgen's ( AMGN) osteoporosis drug denosumab. If approved, Amgen will market the drug under the brand name Prolia. Oct. 22 FDA's approval decision date for Acorda's drug Amaya. Oct. 24-28 The Obesity Society annual meeting convenes in Washington, D.C. Detailed data from phase III studies of three closely watched weight-loss drugs will be presented at the meeting: Arena Pharmaceuticals' ( ARNA) lorcaserin, Vivus' ( VVUS) Qnexa and Orexigen Therapeutics' ( OREX) Contrave.